New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
08:05 EDTALNYAlnylam, collaborators present new clinical data for patisiran
Alnylam Pharmaceuticals and collaborators announced new clinical data for patisiran, an RNAi therapeutic targeting transthyretin in development for the treatment of TTR-mediated amyloidosis. These data are being presented at the International Symposium on Amyloidosis held April 27 – May 1 in Indianapolis, Indiana. First, the company presented updated Phase 2 results in patients with Familial Amyloidotic Polyneuropathy confirming robust TTR knockdown of up to 96% with a mean TTR knockdown of approximately 80%. Further, Alnylam presented preliminary results from the open-label extension study with patisiran in patients that were enrolled in the Phase 2 study. Preliminary results from the OLE study showed that multiple doses of patisiran achieved sustained knockdown of serum TTR protein levels at the 80% target level through 168 days. Moreover, OLE results showed a favorable tolerability profile with up to eight doses administered. Finally, the company presented results of a natural history, cross-sectional analysis study of 283 FAP patients aimed at measuring the rate of neuropathy progression and its correlation with disease severity. These results provide support for Alnylam’s Phase 3 APOLLO trial where patisiran is being evaluated for its potential efficacy and safety in the FAP indication.
News For ALNY From The Last 14 Days
Check below for free stories on ALNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
08:03 EDTALNYAlnylam receives USPTO Notice of Allowance for Manoharan ’478 patent
Subscribe for More Information
07:22 EDTALNYAlnylam to hold a webinar
Subscribe for More Information
July 15, 2014
07:25 EDTALNYAlnylam to hold a roundtable
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use